Sex hormones and the risk of keratinocyte cancers among women in the United States: A population-based case–control study

Lawrence F. Kuklinski1, Michael S. Zens1, Ann E. Perry2, Anala Gossai1, Heather H. Nelson3 and Margaret R. Karagas1

1 Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH
2 Department of Pathology, Geisel School of Medicine at Dartmouth, Lebanon, NH
3 Division of Epidemiology and Community Health, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

Men are at a higher risk of developing both squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) than women, but there is emerging evidence that women may be experiencing greater increases in the incidence rates of these malignancies than men. One possible explanation is the expanding use of sex steroids among women, although only a few studies have examined this hypothesis. As part of a population-based, case–control study of women in New Hampshire, USA, we sought to evaluate the risk of SCC, BCC, and early-onset BCC in relation to exogenous and endogenous sex hormones. We found that oral contraceptive (OC) use was associated with an increased risk of SCC (OR = 1.4, 95% CI = 1.1–1.8) and BCC (OR = 1.4, 95% CI = 1.0–1.8), particularly high estrogen dose (>50 mg) OC use. Hormone replacement therapy (HRT) use also related to SCC, with an elevated OR largely for progestin use (OR = 1.4, 95% CI = 1.1–1.8). Additionally, both OC use and combination HRT use were associated with more aggressive BCC subtypes. In contrast, menstrual and reproductive history did not appear to influence keratinocyte cancer risk in our data. Our findings provide evidence that use of sex steroids may enhance risk of keratinocyte cancer.

Keratinocyte cancers (KC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the leading invasive carcinomas among people of European descent both in the United States and worldwide.1–4 In addition, population-based studies have observed increasing incidence rates of KCs in various parts of the world.5–8 While death is rare,9,10 the large number of people affected by these cancers, along with high recurrence rates and incidence of second cancers,11 results in significant morbidity. Moreover, the necessary treatment consumes a large portion of total healthcare expenditure.1,2,13

Key words: keratinocyte cancer, sex hormones, oral contraception, hormone replacement therapy

Abbreviations: AK: actinic keratosis; BCC: basal cell carcinoma; BMI: body mass index; CI: confidence interval; HRT: hormone replacement therapy; KC: keratinocyte cancer; OC: oral contraceptives; OR: odds ratio; SCC: squamous cell carcinoma; UVR: ultraviolet radiation

Additional Supporting Information may be found in the online version of this article.

DOI: 10.1002/ijc.30072

History: Received 27 Nov 2015; Accepted 19 Feb 2016; Online 3 Mar 2016

Correspondence to: Margaret R. Karagas, Geisel School of Medicine at Dartmouth, One Medical Center Drive 7927 Rubin Building Lebanon, NH 03756, USA, Tel.: +1-(603)–653-9010, Fax: +1-(603)–653-9093, E-mail: Margaret.R.Karagas@Dartmouth.edu

Material and Methods

Study population

The New Hampshire Skin Cancer Study has been described in detail elsewhere.5,24 Briefly, histologically confirmed cases
of invasive newly diagnosed SCC, BCC, and early-onset BCC (≤50 years of age at time of diagnosis) among residents of New Hampshire aged 25 to 74 years old from July 1993 to June 2009 were identified through a network of dermatology and dermatopathology practices in New Hampshire and surrounding regions.\textsuperscript{23,24} Cases were classified as either SCC or BCC according to the histology of the first diagnosed keratinocyte cancer during the study period. Early-onset BCC cases are a subset of BCC cases. Controls were chosen from either the Center for Medicare enrollment lists (for those ≥65 years old) or from driver’s license records provided by the New Hampshire Department of Transportation (for those <65 years old), and frequency-matched to the age (25–34, 35–44, 45–54, 55–64, 65–69, and 70–74 years) and gender distribution of cases. Controls for SCC and BCC were identical for the period July 1993 to June 2003 of our study while the period July 2007 to June 2009 was limited to SCC and so controls from this phase are unique to the SCC analysis.

To be eligible, participants were required to be English-speaking and have a working telephone number. Cases and controls were interviewed concurrently, and interviewers were masked to the case-control status of study participants and study hypotheses. For cases, we requested the original diagnostic pathology materials, which underwent standardized histopathologic re-review by a study board certified dermatopathologist (A.P.) who documented the presence or absence of actinic keratosis and the level of solar elastosis (mild, moderate, severe) in the dermis adjacent to the tumor as described previously.\textsuperscript{27} Of those eligible, 84% of cases and 73% of controls were interviewed. Only women were selected for inclusion in this study. Informed consent was obtained as required by the Committee for the Protection of Human Subjects at Dartmouth College.

Detailed personal interviews were performed (usually at the participant’s home) to ascertain information on sociodemographic characteristics (including level of education), hair and eye color, smoking status, skin sensitivity to the sun, history of sun burns, and time spent outdoors throughout their lifetime.\textsuperscript{27} Medical history included use of OC and HRT, and for positive responses, age at first and last use, duration of use, and specific type of medication used the longest. To aid in memory recall, pictures and names of common OC and HRT were provided. Reproductive and menstrual history questions included gravidity, parity, age of menarche, and age and type of menopause. Questions regarding OC and HRT use were first administered in October 1995, parity in July 1998, and age of menarche in July 2000. Body mass index (BMI) was calculated based on reported height and weight, variables that were first collected in July 1997.

Statistical analyses

Using logistic regression analysis, we first calculated the age and skin-type adjusted odds ratios (OR) and 95% confidence intervals (CI) for invasive SCC, BCC, and early-onset BCC by OC use and HRT as a dichotomous variable (ever vs. never use). Ever OC use was defined as use for 3 months or longer. Those who reported never having used an OC or whose use was ≤3 months were classified as nonusers. A similar definition was applied to HRT use, and these analyses were restricted to post-menopausal women. In addition to overall effects of OC use, we examined the years since last OC use (<25 years, ≥25 years), duration of OC use (<2 years, 2–3 years, 3–6 years, ≥7 years), and for HRT use years since last use (current use, former use), and duration of use (<5 years, ≥5 years) with nonusers as the reference group. These cutoffs were made to maintain consistency with our previous study, which performed a similar analysis. Models also included variables for OC use based on formulation (any estrogen or estrogen + progestin) and estrogen dose (<50 mg or ≥50 mg). To assess both latency and duration of OC use, we computed ORs for total duration of use (<2 years, 2–6 years, ≥7 years) by time since last use (<25 years or ≥25 years). We used likelihood ratio tests to detect any interaction between OC use and HRT.

To evaluate the possible effects of endogenous estrogens on KC risk, we examined age of menarche (<13 years old, 13–15 years old (referent), >15 years old), age of menopause (<40 years old, 40–54 years old (referent), ≥55 years old), type of menopause (surgical and natural (referent)), and parity both as a categorical variable (0 (referent), 1–2, 3–4, ≥5) and a continuous variable. Age at menarche and menopause were grouped according to ages that have historically been used in analyzing these reproductive factors in relation to cancer risk.\textsuperscript{28} The duration of ovulation was calculated as the number of years between menarche and menopause for women who reached menopause without surgery or medication therapy.

To determine whether associations differed by characteristics of tumors based on pathology re-review of the original diagnostic tumor, we conducted a case-case analysis using.
### Table 1. Selected characteristics of keratinocyte cancer cases and controls among women from the New Hampshire Skin Cancer Study

|                          | SCC controls \(N = 746\) | SCC cases \(N = 570\) | BCC controls \(N = 550\) | BCC cases \(N = 633\) | Early-onset BCC controls \(N = 246\) | Early-onset BCC cases \(N = 362\) |
|--------------------------|---------------------------|-----------------------|--------------------------|-----------------------|----------------------------------|----------------------------------|
| **Age (yr)**             |                           |                       |                          |                       |                                  |                                  |
| 25–44                    | 139 (18.6)                | 23 (4.0)              | 135 (24.5)              | 197 (31.1)            | 139 (56.5)                       | 197 (54.4)                       |
| 45–54                    | 163 (21.8)                | 79 (13.9)             | 131 (23.8)              | 207 (32.7)            | 107 (43.5)                       | 165 (45.6)                       |
| 55–64                    | 160 (21.4)                | 169 (29.6)            | 98 (17.8)               | 104 (16.4)            |                                  |                                  |
| 65–69                    | 150 (20.1)                | 144 (25.3)            | 98 (17.8)               | 59 (9.3)              |                                  |                                  |
| 70–74                    | 134 (18.0)                | 155 (27.2)            | 88 (16.0)               | 60 (10.4)             |                                  |                                  |
| **Highest level of education**          |                           |                       |                          |                       |                                  |                                  |
| High school              | 313 (42.0)                | 205 (36.0)            | 242 (44.1)              | 186 (29.6)            | 66 (26.8)                        | 74 (20.6)                        |
| College                  | 293 (39.3)                | 230 (40.4)            | 212 (38.6)              | 289 (45.9)            | 133 (54.1)                       | 191 (53.2)                       |
| Graduate or professional school | 139 (18.7)                | 134 (23.6)            | 95 (17.3)               | 154 (24.5)            | 47 (19.1)                        | 94 (26.2)                        |
| **Cigarette smoking history**            |                           |                       |                          |                       |                                  |                                  |
| Never                    | 333 (44.6)                | 235 (41.3)            | 263 (47.8)              | 334 (52.9)            | 121 (49.2)                       | 199 (55.1)                       |
| Former                   | 285 (38.2)                | 244 (42.9)            | 191 (34.7)              | 201 (31.9)            | 75 (30.5)                        | 102 (28.3)                       |
| Current                  | 128 (17.2)                | 90 (15.8)             | 96 (17.5)               | 96 (15.2)             | 50 (20.3)                        | 60 (16.6)                        |
| **Body mass index (kg/m²)**           |                           |                       |                          |                       |                                  |                                  |
| <18.5 (underweight)      | 9 (1.5)                   | 16 (3.2)              | 7 (1.7)                 | 13 (2.6)              | 2 (0.9)                          | 12 (3.9)                         |
| 18.5–24.9 (normal)       | 281 (66.8)                | 234 (46.6)            | 199 (49.1)              | 298 (60.1)            | 117 (54.7)                       | 195 (63.1)                       |
| 25–29 (overweight)       | 157 (26.1)                | 151 (30.1)            | 110 (27.2)              | 112 (22.6)            | 53 (24.8)                        | 64 (20.7)                        |
| ≥30 (obese)              | 154 (25.6)                | 101 (20.1)            | 89 (22.0)               | 73 (14.7)             | 42 (19.6)                        | 38 (12.3)                        |
| **No. severe sunburns**  |                           |                       |                          |                       |                                  |                                  |
| 0–2                      | 391 (58.7)                | 233 (44.9)            | 303 (59.9)              | 269 (46.1)            | 113 (48.9)                       | 131 (39.6)                       |
| ≥3                       | 275 (41.3)                | 286 (55.1)            | 203 (40.1)              | 314 (53.9)            | 118 (51.1)                       | 200 (60.4)                       |
| **Hours recreational sun exposure in warm months 9 a.m. to 5 p.m.** |                           |                       |                          |                       |                                  |                                  |
| T1 (0–7,864 h)           | 262 (39.8)                | 128 (24.6)            | 238 (47.4)              | 262 (43.9)            | 128 (55.4)                       | 177 (51.3)                       |
| T2 (7,865–11,601 h)      | 205 (31.1)                | 137 (26.3)            | 157 (31.3)              | 173 (29.0)            | 75 (30.5)                        | 105 (30.4)                       |
| T3 (11,602–44,113 h)     | 192 (29.1)                | 256 (49.1)            | 107 (21.3)              | 162 (27.1)            | 28 (12.1)                        | 63 (18.3)                        |
| **Hours total sun exposure in warm months 9 a.m. to 5 p.m.** |                           |                       |                          |                       |                                  |                                  |
| T1 (0–11,978 h)          | 327 (69.8)                | 162 (31.4)            | 279 (55.8)              | 327 (55.3)            | 157 (68.3)                       | 230 (67.4)                       |
| T2 (11,979–19,335 h)     | 201 (30.6)                | 205 (39.7)            | 142 (28.4)              | 187 (31.6)            | 61 (26.5)                        | 91 (26.7)                        |
| T3 (19,336–48123 h)      | 128 (19.5)                | 149 (28.9)            | 79 (15.8)               | 77 (13.0)             | 12 (5.2)                         | 20 (5.9)                         |
| **Sun sensitivity to first solar exposure** |                           |                       |                          |                       |                                  |                                  |
| Tan                      | 89 (12.0)                 | 42 (7.4)              | 54 (9.9)                | 48 (7.7)              | 20 (8.1)                         | 24 (6.7)                         |
| Mild burn then tan       | 316 (42.5)                | 244 (43.0)            | 222 (40.5)              | 249 (39.7)            | 116 (47.2)                       | 146 (40.6)                       |
| Burn then peel           | 260 (34.9)                | 223 (39.3)            | 207 (37.8)              | 282 (45.0)            | 93 (37.8)                        | 160 (44.4)                       |
| Burn then blister        | 79 (10.6)                 | 59 (10.4)             | 65 (11.9)               | 48 (7.7)              | 17 (6.9)                         | 30 (8.3)                         |
| **Anatomic site of keratinocyte cancer** |                           |                       |                          |                       |                                  |                                  |
| Head and neck            | 238 (42.5)                | 365 (59.7)            | 208 (58.9)              |                       |                                  |                                  |
| Upper and lower limbs    | 231 (41.3)                | 69 (11.3)             | 40 (11.3)               |                       |                                  |                                  |
| Thorax and abdomen       | 91 (16.3)                 | 177 (29.0)            | 105 (29.7)              |                       |                                  |                                  |
unconditional logistic regression for subgroups of SCC and BCC by severity of solar elastosis (severe vs. none-moderate), for SCC by the presence of actinic keratoses (present vs. absent), for BCC by histology (aggressive types including infiltrative, sclerosing, morpheaform, and micronodular vs. other), and for both types by anatomic site of the keratinocyte lesion.

In our models, we assessed the effects of potential confounding factors including skin reaction to first sun exposure (painful or blistering sunburn, tan or burn then tan), education level (less than college, college, graduate school), family history of KC, number of hours spent outdoors from 9 a.m. to 5 p.m. during the summer and recreationally, number of lifetime painful sunburns, and smoking status (never, former, current). Final models were then constructed using each hormone variable and confounders that changed the ORs by more than 10% or were deemed clinically relevant.29 In our analysis, we ultimately adjusted for reference age as a continuous variable and skin reaction following first sun exposure as a categorical variable (tan, mild burn then tan, peeling skin after a painful burn, blistering after a painful burn). All statistical analyses were two-sided, and significance was assessed at the 0.05 level. Analyses were conducted with the statistical software SAS version 9.4.

Results

Study population characteristics

Interviews containing questions of OC use or HRT use were administered to 570 SCC cases and 746 SCC controls, and 550 BCC cases and 633 BCC controls. Of these, OC or HRT use was recorded as ever or never use by 558 (97.9%) SCC cases and 716 (96.0%) SCC controls, and 604 (95.4%) BCC cases, and 520 (94.5%) BCC controls (Table 1). The early-onset BCC subgroup included 362 cases and 246 controls of whom 347 (95.9%) and 228 (92.7%) had sex steroid use data. After adjustment for reference age and skin sensitivity to first solar exposure in the summer, we observed an elevated OR (OR 5 1.4, 95% CI 5 1.0–1.8), and early-onset BCC (OR 5 1.4, 95% CI 5 1.0–2.1) in relation to OC use compared to nonuse (Table 2). Longer durations of OC use (87 years) were associated with higher ORs of SCC (OR 5 1.5, 95% CI 5 1.1–2.0), BCC (OR 5 1.5, 95% CI 5 1.1–2.1), and early-onset BCC (OR 5 1.6, 95% CI 5 1.0–2.7) compared to shorter duration of use (0 years). The magnitude of the associations with SCC appeared stronger for women with a more remote history of OC use (<25 years, OR 5 1.0, 95% CI 5 0.7–1.6; >25 years, OR 5 2.1, 95% CI 5 1.5–3.2) while for the association with BCC risk did not appear to differ by time since last exposure (<25 years, OR 5 1.3, 95% CI 5 1.0–1.8; >25 years, OR 5 1.5, 95% CI 5 1.0–2.1). For SCC, an increasing trend in

---

### Table 1. Selected characteristics of keratinocyte cancer cases and controls among women from the New Hampshire Skin Cancer Study (Continued)

| Amount of solar elastoses | SCC controls (N = 746) N (%) | SCC cases (N = 570) N (%) | BCC controls (N = 550) N (%) | BCC cases (N = 633) N (%) | Early-onset BCC controls1 (N = 246) N (%) | Early-onset BCC cases (N = 362) N (%) |
|---------------------------|-----------------------------|---------------------------|-------------------------------|---------------------------|------------------------------------------|-------------------------------------|
| Absent                    | 2 (0.6)                    | 5 (1.4)                   | 2 (0.9)                       |                           |                                          |                                     |
| Minimum                   | 40 (11.5)                  | 22 (6.4)                  | 33 (15.6)                     |                           |                                          |                                     |
| Moderate                  | 96 (27.5)                  | 76 (22.0)                 | 71 (33.6)                     |                           |                                          |                                     |
| Severe                    | 211 (60.5)                 | 243 (70.2)                | 105 (49.8)                    |                           |                                          |                                     |

1Early-onset BCC defined as age <50 years old at time of diagnosis.
2Level of education is missing from one SCC case, one control, and three BCC cases (three early-onset BCC cases).
3Smoking status is missing from one SCC case, two BCC cases (one early-onset BCC cases).
4Body mass index calculated from subject height and weight, variables that were collected starting July 1997.
5The number of severe, painful sunburns is missing from 80 SCC controls, 51 SCC cases, 44 BCC controls (eight early-onset) and 50 BCC cases (31 early-onset).
6Hours of recreational sun exposure during warm months between 9 a.m. and 5 p.m. is missing from 87 SCC controls and 49 SCC cases, 48 BCC controls (eight early-onset) and 36 BCC cases (17 early-onset). Tertile cut points based on the hours of sun exposure in controls.
7Hours of total sun exposure in warm months between 9 a.m. and 5 p.m. is missing from 90 SCC controls and 54 SCC cases, 50 BCC controls (nine early-onset BCC cases) and 42 BCC cases (21 early-onset BCC cases). Tertile cut points based on the hours sun exposure in controls.
8Sun sensitivity to first solar exposure is missing from two SCC controls, two SCC cases; six BCC cases (two early-onset BCC cases).
Table 2. Odds ratios (95% CI) of keratinocyte cancers in relation to oral contraceptive (OC) use, hormone replacement therapy (HRT) use, and reproductive factors

|                              | SCC controls | SCC cases | BCC controls | BCC cases | Early-onset BCC controls | Early-onset BCC cases |
|------------------------------|--------------|-----------|--------------|-----------|--------------------------|----------------------|
|                              | (N = 746)    | (N = 570) | (N = 550)    | (N = 633) | (N = 246)                | (N = 362)            |
| SCC controls                 |              |           |              |           |                          |                      |
| Oral contraception use³      |              |           |              |           |                          |                      |
| No                           | 307 (43.2)   | 270 (48.6)| 236 (45.8)   | 200 (33.6)| 49 (21.5)                | 57 (16.6)            |
| Yes                          | 404 (56.8)   | 286 (51.4)| 279 (54.2)   | 396 (66.4)| 179 (78.5)               | 287 (83.4)           |
| Age at last OC use           |              |           |              |           |                          |                      |
| Nonuser                      | 307 (45.0)   | 270 (49.3)| 236 (48.4)   | 200 (36.2)| 49 (24.1)                | 57 (18.8)            |
| <29 yr old                   | 173 (25.4)   | 100 (18.2)| 120 (24.6)   | 168 (30.4)| 97 (47.8)                | 144 (47.5)           |
| ≥29 yr old                   | 202 (29.6)   | 178 (32.5)| 132 (27.0)   | 185 (33.5)| 57 (28.1)                | 102 (33.7)           |
| Continuous                   |              |           |              |           |                          |                      |
|                              | p<0.018      | p<0.019   | p<0.091      |           |                          |                      |
| Duration of OC use           |              |           |              |           |                          |                      |
| Nonuser                      | 307 (43.3)   | 270 (48.6)| 236 (46.0)   | 200 (33.6)| 49 (21.6)                | 57 (16.6)            |
| ≤2 yr                        | 60 (8.5)     | 35 (6.3)  | 41 (8.0)     | 64 (10.8)| 22 (9.7)                 | 44 (12.8)            |
| 3–6 yr                       | 157 (22.1)   | 106 (19.1)| 119 (23.2)   | 149 (25.0)| 87 (38.3)                | 111 (32.4)           |
| ≥7 yr                        | 185 (26.1)   | 144 (25.9)| 117 (22.8)   | 182 (30.6)| 69 (30.4)                | 131 (38.2)           |
| Continuous                   |              |           |              |           |                          |                      |
|                              | p<0.030      | p<0.052   | p<0.047      |           |                          |                      |
| Years since last OC use      |              |           |              |           |                          |                      |
| Nonuser                      | 307 (52.6)   | 270 (62.5)| 236 (46.2)   | 200 (33.7)| 49 (21.7)                | 57 (16.6)            |
| <25 yr                       | 213 (36.5)   | 77 (17.8) | 211 (41.3)   | 308 (51.9)| 162 (71.7)               | 254 (74.1)           |
| ≥25 yr                       | 64 (11.0)    | 85 (19.7) | 64 (12.5)    | 85 (14.3)| 15 (6.6)                 | 32 (9.3)             |
| Continuous                   |              |           |              |           |                          |                      |
|                              | p<0.020      | p<0.150   | p<0.895      |           |                          |                      |
| OC formulation               |              |           |              |           |                          |                      |
| Nonuser                      | 307 (53.3)   | 270 (59.1)| 236 (55.0)   | 200 (39.9)| 49 (37.7)                | 57 (27.3)            |
| Estrogen dose, ≤50 mg        | 193 (38.6)   | 120 (30.8)| 135 (36.4)   | 166 (45.4)| 91 (65.0)                | 119 (67.6)           |
| Estrogen dose, >50 mg        | 211 (40.7)   | 166 (38.1)| 144 (37.9)   | 230 (53.5)| 88 (64.2)                | 168 (74.7)           |
| Combination                  | 266 (46.4)   | 186 (40.8)| 193 (45.0)   | 296 (59.7)| 136 (73.5)               | 230 (80.1)           |
| Sequential                   | 182 (37.2)   | 141 (34.3)| 124 (34.4)   | 197 (49.6)| 81 (62.3)                | 152 (72.7)           |
|                              |              |           |              |           |                          |                      |
|                              | p<0.020      | p<0.150   | p<0.895      |           |                          |                      |
| Hormone replacement therapy use³  |            |           |              |           |                          |                      |
| No                           | 310 (58.7)   | 254 (49.7)| 207 (60.3)   | 194 (58.1)| 194 (60.3)               | 194 (58.1)           |
| Yes                          | 218 (41.3)   | 257 (50.3)| 136 (39.7)   | 140 (41.9)| 136 (39.7)               | 140 (41.9)           |
| Exclusive estrogen           | 146 (32.0)   | 155 (37.9)| 88 (29.8)    | 95 (32.9)| 11 (0.8–1.6)             | 11 (0.8–1.6)         |
| Estrogen + progestin         | 45 (12.7)    | 73 (22.3) | 29 (12.3)    | 32 (14.2)| 10 (0.5–1.7)             | 10 (0.5–1.7)         |
|                          | SCC controls (N = 746) | SCC cases (N = 570) | OR (95% CI)² | BCC controls (N = 550) | BCC cases (N = 633) | OR (95% CI) | Early-onset BCC controls¹ (N = 246) | Early-onset BCC cases (N = 362) | OR (95% CI) |
|--------------------------|------------------------|---------------------|--------------|------------------------|---------------------|-------------|-------------------------------------|---------------------------------|-------------|
| **Age at first HRT use** |                        |                     |              |                        |                     |             |                                     |                                  |             |
| Nonuser                  | 310 (58.7)             | 254 (49.9)          | 1.0 (ref)    | 207 (56.3)             | 194 (58.1)          | 1.0 (ref)   |                                     |                                  |             |
| <48 yr old               | 108 (20.5)             | 111 (21.8)          | 1.3 (0.9–1.7) | 61 (17.8)              | 60 (18.0)           | 0.9 (0.6–1.4) |                                     |                                  |             |
| ≥48 yr old               | 110 (20.8)             | 144 (28.3)          | 1.5 (1.1–2.0) | 75 (21.9)              | 80 (24.0)           | 1.1 (0.8–1.6) |                                     |                                  |             |
| Continuous               | $p_{trend} < 0.004$    |                     |              | $p_{trend} < 0.690$   |                     |             |                                     |                                  |             |
| **Duration of HRT use**  |                        |                     |              |                        |                     |             |                                     |                                  |             |
| Nonuser                  | 310 (58.9)             | 254 (50.3)          | 1.0 (ref)    | 207 (60.7)             | 194 (58.6)          | 1.0 (ref)   |                                     |                                  |             |
| >0–≤5 yr                 | 83 (15.8)              | 71 (14.1)           | 1.1 (0.7–1.5) | 55 (16.1)              | 57 (17.2)           | 0.9 (0.6–1.4) |                                     |                                  |             |
| >5 yr                    | 133 (25.3)             | 180 (35.6)          | 1.6 (1.2–2.1) | 79 (23.2)              | 80 (24.2)           | 1.1 (0.8–1.6) |                                     |                                  |             |
| Continuous               | $p_{trend} < 0.057$    |                     |              | $p_{trend} < 0.566$   |                     |             |                                     |                                  |             |
| **Years since last HRT use** |                    |                     |              |                        |                     |             |                                     |                                  |             |
| Nonuser                  | 310 (60.5)             | 254 (50.7)          | 1.0 (ref)    | 207 (63.1)             | 194 (59.5)          | 1.0 (ref)   |                                     |                                  |             |
| Current user             | 163 (31.8)             | 190 (37.9)          | 1.4 (1.1–1.8) | 89 (27.1)              | 103 (31.6)          | 1.2 (0.8–1.7) |                                     |                                  |             |
| Former (>1 yr)           | 39 (7.6)               | 57 (11.4)           | 1.6 (1.0–2.5) | 32 (9.8)               | 29 (8.9)            | 1.0 (0.6–1.7) |                                     |                                  |             |
| Continuous               | $p_{trend} < 0.771$    |                     |              | $p_{trend} < 0.696$   |                     |             |                                     |                                  |             |
| **Age at menarche (yr)** |                        |                     |              |                        |                     |             |                                     |                                  |             |
| <13                      | 178 (43.3)             | 120 (41.4)          | 1.0 (0.7–1.4) | 104 (47.9)             | 112 (43.2)          | 0.8 (0.5–1.2) | 78 (51.0)                           | 103 (45.2)          | 0.8 (0.5–1.2) |
| 13–15                    | 206 (50.1)             | 155 (53.4)          | 1.0 (ref)    | 100 (46.1)             | 130 (50.2)          | 1.0 (ref)   | 68 (44.4)                           | 112 (49.1)          | 1.0 (ref)   |
| >15                      | 27 (6.6)               | 15 (5.2)            | 0.9 (0.4–1.8) | 13 (6.0)               | 17 (6.6)            | 1.2 (0.5–2.6) | 4 (2.6)                             | 13 (5.7)            | 1.2 (0.4–3.2) |
| Continuous               | $p_{trend} < 0.346$    |                     |              | $p_{trend} < 0.128$   |                     |             |                                     |                                  |             |
| **Menopause type**       |                        |                     |              |                        |                     |             |                                     |                                  |             |
| Nonsurgical or medication induced | 329 (46.4)         | 329 (59.3)          | 1.0 (ref)    | 208 (40.5)             | 197 (33.2)          | 1.0 (ref)   | 35 (15.6)                           | 48 (14.1)          | 1.0 (ref)   |
| All surgical types       | 182 (25.7)             | 162 (29.2)          | 0.9 (0.7–1.1) | 121 (23.6)             | 121 (20.4)          | 1.0 (0.8–1.4) | 23 (10.3)                           | 40 (11.8)          | 1.3 (0.7–2.5) |
| Bilateral oophorectomy   | 30 (4.2)               | 20 (3.6)            | 0.6 (0.4–1.2) | 21 (4.1)               | 21 (3.5)            | 1.1 (0.6–2.1) | 3 (1.3)                             | 4 (1.2)            | 1.0 (0.2–4.6) |
| Unilateral oophorectomy  | 91 (12.8)              | 87 (15.7)           | 0.9 (0.7–1.3) | 57 (11.1)              | 57 (9.6)            | 1.1 (0.7–1.7) | 10 (4.5)                            | 15 (4.4)           | 1.2 (0.5–2.9) |
| Hysterectomy             | 56 (7.9)               | 50 (9.0)            | 0.9 (0.6–1.3) | 40 (7.8)               | 41 (6.9)            | 1.0 (0.6–1.6) | 9 (4.0)                             | 21 (6.2)           | 1.7 (0.7–4.1) |

---

*Kuklinski et al.*

Int. J. Cancer: 139, 300–309 (2016) © 2016 UICC
|                                | SCC controls  | SCC cases  | BCC controls  | BCC cases  | Early-onset BCC controls | Early-onset BCC cases |
|--------------------------------|---------------|------------|---------------|------------|--------------------------|----------------------|
|                                | \( N = 746 \) | \( N = 570 \) | \( N = 550 \) | \( N = 633 \) | \( N = 246 \) | \( N = 362 \) |
| **Age at natural menopause (yr)** |               |            |               |            |                          |                      |
| < 40                           | 14 (4.4)      | 11 (3.4)   | 0.9 (0.4–2.0) | 12 (6.0)   | 5 (2.6)                  | 0.4 (0.1–1.2)       |
| 40–54                          | 255 (79.4)    | 249 (77.6) | 1.0 (ref)     | 159 (79.1) | 166 (84.7)               | 1.0 (ref)           |
| ≥55                            | 52 (16.2)     | 61 (19.0)  | 1.1 (0.7–1.6) | 30 (14.9)  | 25 (12.8)                | 0.9 (0.5–1.6)       |
| Continuous                      |               |            |               |            |                          |                      |
| \( p_{\text{trend}} < 0.768 \) |               |            |               |            |                          |                      |
| Age at bilateral oophorectomy (yr) |               |            |               |            |                          |                      |
| < 40                           | 16 (53.3)     | 10 (50.0)  | 0.8 (0.2–2.7) | 11 (52.4)  | 14 (66.7)                | 1.9 (0.5–7.9)       |
| 40–54                          | 13 (43.3)     | 10 (50.0)  | 1.0 (ref)     | 10 (47.6)  | 7 (33.3)                 | 1.0 (ref)           |
| Continuous                      |               |            |               |            |                          |                      |
| \( p_{\text{trend}} < 0.331 \) |               |            |               |            |                          |                      |
| Parity7                         |               |            |               |            |                          |                      |
| 0                              | 71 (11.8)     | 53 (10.6)  | 1.0 (ref)     | 49 (12.1)  | 73 (14.9)                | 1.0 (ref)           |
| 1–2                            | 291 (48.3)    | 221 (44.1) | 1.0 (0.6–1.5) | 203 (50.0) | 256 (52.2)               | 0.8 (0.6–1.3)       |
| 3–4                            | 185 (30.7)    | 177 (35.3) | 0.8 (0.5–1.3) | 115 (28.3) | 139 (28.4)               | 0.9 (0.6–1.5)       |
| ≥5                             | 55 (9.1)      | 50 (10.0)  | 0.7 (0.4–1.2) | 39 (9.6)   | 22 (4.5)                 | 0.5 (0.3–1.0)       |
| Continuous                      |               |            |               |            |                          |                      |
| \( p_{\text{trend}} < 0.252 \) |               |            |               |            |                          |                      |
| Duration of ovulation8 (yr)     |               |            |               |            |                          |                      |
| ≤29                            | 19 (11.0)     | 11 (7.3)   | 1.0 (ref)     | 10 (16.1)  | 6 (10.9)                 | 1.0 (ref)           |
| >29–35                         | 49 (28.3)     | 34 (22.5)  | 1.3 (0.5–3.2) | 19 (30.6)  | 16 (29.1)                | 1.1 (0.3–3.8)       |
| >35–39                         | 59 (34.1)     | 63 (41.7)  | 1.8 (0.7–4.1) | 21 (33.9)  | 26 (47.3)                | 2.2 (0.6–7.6)       |
| >39                            | 46 (26.6)     | 43 (28.5)  | 1.5 (0.6–3.7) | 12 (19.4)  | 7 (12.7)                 | 1.5 (0.3–6.8)       |
| Continuous                      |               |            |               |            |                          |                      |
| \( p_{\text{trend}} < 0.270 \) |               |            |               |            |                          |                      |

1Early-onset BCC defined as age ≤50 years old at time of diagnosis.
2Odds ratios and 95% confidence intervals adjusted for reference age and skin sensitivity to first solar exposure.
3Oral contraceptive use and hormone replacement therapy questions were administered beginning on the 5th of October, 1995.
4Hormone replacement therapies are restricted to those women who have begun menopause.
5Age of menarche was administered beginning on the 1st of July 2000.
6Menopause induced by medication, or nonsurgical therapies were excluded from this analysis.
7Gravidity and parity questions were administered beginning on the 1st of July 1998.
8Endogenous estrogen exposure was calculated as the number of years between menarche and menopause in women who had reached menopause without surgery or medication therapy.
Table 3. Case-case odds ratios (95% CI) of basal cell carcinoma (BCC) in relation to oral contraceptive and hormone replacement therapy use by subgroups according to histology

| Oral contraceptive use          | Nonaggressive histology, N (%) | Aggressive histology, N (%) | OR (95% CI)1 |
|---------------------------------|--------------------------------|-----------------------------|--------------|
| Nonuser                         | 449 (38.5)                     | 5 (16.7)                    | 1.0 (ref)    |
| Any user                        | 717 (61.5)                     | 25 (83.3)                   | 3.3 (1.3–8.8)|
| Hormone replacement therapy     |                                |                             |              |
| Nonuser                         | 821 (69.9)                     | 20 (66.7)                   | 1.0 (ref)    |
| Any user                        | 354 (30.1)                     | 10 (33.3)                   | 1.2 (0.5–2.6)|
| Any estrogen                    | 306 (27.2)                     | 9 (31.0)                    | 1.2 (0.5–2.7)|
| Exclusive estrogen              | 230 (21.9)                     | 3 (13.0)                    | 0.5 (0.2–1.9)|
| Estrogen + progestin            | 76 (8.5)                       | 6 (23.1)                    | 3.3 (1.3–8.5)|

1 Odds ratios and 95% confidence intervals adjusted for reference age and skin sensitivity to first solar exposure.

the ORs with duration of use was present among those who used OCs in the more distant past (≤2 years: OR = 1.7, 95% CI = 1.0–2.8, 3–6 years: OR = 2.6, 95% CI = 1.4–4.8, ≥7 years: OR = 3.0, 95% CI = 1.3–6.8; P<0.06). In contrast, for BCC, trends by duration of use were observed among more recent users (BCC, ≤2 years: OR = 1.4, 95% CI = 0.8–2.3, 3–6 years: OR = 1.3, 95% CI = 0.9–2.0, ≥7 years: OR = 1.7, 95% CI = 1.2–2.4; P<0.96. Early-onset BCC, ≤2 years: OR = 1.2, 95% CI = 0.7–2.2, 3–6 years: OR = 1.1, 95% CI = 0.7–1.9, ≥7 years: OR = 1.6, 95% CI = 1.0–2.6; P<0.65) (Supporting Information Table 1). Women who used OC with >50 mg of estrogen had somewhat higher ORs for SCC and early-onset BCC than those who used OC with lower estrogen doses (Table 2). There did not appear to be appreciable differences by combination versus sequential OC use (Table 2).

HRT use also was associated with increased risk of SCC (OR =1.4, 95% CI = 1.1–1.8). Both current and former HRT use was associated with an increased risk of SCC (current users: OR = 1.4, 95% CI = 1.1–1.8, former users: OR = 1.6, 95% CI = 1.0–2.5), and ORs increased with older age at first use (P<0.004) (Table 2). Combined estrogen and progestin use was associated with a higher OR than estrogen alone (Table 2).

We then examined the effects of OC use alone, HRT use alone, and combination of OC and HRT use (Supporting Information Table 2). SCC risk was highest among women who used both OC and HRT (OR = 1.9, 95% CI = 1.4–2.7) and slightly so for BCC (OR = 1.4, 95% CI = 1.0–2.1).

Neither age of menarche nor age of menopause was related to the risk of keratinocyte cancers (Table 2). With natural menopause as the referent group, bilateral oophorectomy was associated with a lower odds of SCC (OR = 0.6, 95% CI = 0.4–1.2) but with wide CIs. Parity was unrelated to risk of KC (Table 2). Longer total duration of endogenous estrogen exposure was associated with a somewhat higher risk of SCC and BCC, but not statistically significantly so. Stratification by BMI did not indicate effect modification in KC associations with OC or HRT (Supporting Information Table 3).

In our case-case analyses, OC use was related to SCCs and BCCs without histologic evidence of severe solar elastosis (Supporting Information Table 4), and SCCs without evidence of actinic keratosis (Supporting Information Table 5). In contrast, for HRT use there was a positive association with BCCs with severe elastosis compared to those with none to moderate elastosis (Supporting Information Table 4), and SCCs with associated actinic keratosis (Supporting Information Table 5). No clear patterns were observed by anatomic site (Supporting Information Table 6). Notably, both OC and combination HRT users were more likely to have an aggressive BCC subtype (Table 3).

Discussion

In our population-based case–control study, we found associations between both OC and HRT use and newly diagnosed SCC. Additionally, use of OCs related to newly diagnosed BCC, and both OC and HRT use were associated with aggressive BCC histology. No clear associations were observed for factors related to endogenous estrogens including timing of menarche, age or type of menopause, and parity.

There are relatively few prior cohort studies that have examined KC risk in relation to OC use. A large cohort study from the United Kingdom found no association between use of OCs and “nonmelanoma skin cancer” (presumably BCC and SCC combined).30 While this study had the benefit of a large sample size (n = 29,875 cases), the study population was young (aged between 25 and 39 years) and therefore had only 83 KC events. Additionally, it relied on hospital referral codes rather than histologic diagnosis, leaving open the possibility of diagnostic misclassification and making BCC- and SCC-specific risk calculations impossible. Additionally, a Danish cohort study, found no OC-associated increased risk
of SCC either overall or by duration or time since last use. 22 This study likewise had limited statistical power due to the small number of SCC cases (n = 76). In a case–control analysis of pre-paid health plan data from California, the OR for SCC associated with prior OC use was 2.4, but attenuated to 2.0 and was no longer statistically significant in the multivariate analysis. 20 In an earlier report based on the first and second diagnosis periods of our study (1 July 1993 to 30 June 1995, and 1 July 1997 to 30 March 2000), we found an increased risk of SCC among women who had used OCs ≥25 years ago, with a trend in risk by duration of use. 21 We performed a similar analysis with data from two additional study phases, and our findings remain largely unchanged. Our observation that OC formulations with higher doses of estrogen were associated with increased risk of SCC occurrence will need to be confirmed in future studies.

We found an association between OC use and BCC, which was similar to the findings from the Danish cohort (n = 1,175 BCC cases), in which BCC risk was slightly increased overall and among past users, but not current users. 22 Both in our study and in the Danish study, higher doses of estrogen were associated with increased risk. Our findings further suggest that the association may be stronger for early-onset BCC, and BCCs with a more aggressive phenotype. While these results need to be confirmed by other studies, our observations support the hypothesis that risk factors for early-onset BCC may differ from those of later-onset disease. 25,31

The published literature concerning HRT use and KC is also relatively scant. A retrospective analysis of the Women's Health Initiative examined records of 27,347 postmenopausal women with follow-up period of 6 years and found no relation with nonmelanoma skin cancers and HRT use. 32 This study relied on self-reported skin cancer diagnoses and hence lacked histologic information. In a Danish cohort, the reported relative risk was 1.35 for every 5 years of HRT exposure. 22 We found a similarly increased risk specific to SCC, which appeared to be independent of prior exogenous hormone exposure as the risk was unchanged when excluding those with prior OC use. Our findings raise the possibility of a synergistic effect among those with HRT and OC use although we had limited statistical power to detect interactions. The risk for SCC was especially strong among those who used combined estrogen and progestin HRT, an effect previously described for other cancers including breast and possibly ovarian cancer. 33–37 Thus, the potential effects of HRT on KC occurrence warrant further investigation.

Estrogen receptors are present on the surface of keratinocytes and when activated induce proliferation. 38 Estrogen receptor activation further may alter the DNA repair capacity of keratinocytes leading to increased susceptibility to repeated environmental insults. 39,40 Indeed, our earlier study provided evidence of a potential modifying role of altered DNA repair capacity, with findings of an interaction for SCC between OC use and an XPD genotype. 21 Another potential mechanism in theory could be estrogen-induced photosensitization. 41–43 In support of this, we found that degree of solar elastosis was more severe in BCC cases who had taken HRT. Solar elastosis is a marker of chronic ultraviolet radiation exposure and has been shown in a meta-analysis to be related to risk of BCC. 44 An association between OC or HRT exposure and aggressive subtypes of BCC has not previously been reported but if true, this would suggest that increased surveillance and early identification is important among women taking sex steroids.

Increased physiologic exposure to sex hormones as measured by number of years spent ovulating, age at first pregnancy, and number of pregnancies have been implicated in some cancers in women, 45–50 although the effects on keratinocyte cancer are not well documented. A single study in the literature reported that a large number of deliveries (≥10) was associated with a reduced incidence of BCC in a Finnish population. 49 In addition, a meta-analysis found that women with a late age at first pregnancy were at increased risk of melanoma while having more than one child resulted in a lower risk. 51 We did not detect clear associations with parity, reproductive factors, or cumulative years spent menstruating. There was the suggestion of a trend toward increased risk among women with longer duration of ovulation, but we lacked statistical power to observe this trend among those ovulating longest. Future studies may be able to more clearly define a possible risk due to increased endogenous estrogen exposure.

As with all retrospective studies, an important limitation in our study is recall bias, which may have affected the reported history of OC and HRT use. We provided subjects with photo-aids in order to assist in recall of medications, however, timing and duration of use were solely based on subject recollection. Another limitation is that a large portion of our study population was older and these women were likely to have been exposed to different OC and/or HRT formulations than are currently available. For example, modern OC formulations have greatly reduced levels of estrogen and therefore current OC users may not experience the same risks we observed. Finally, only limited conclusions can be drawn from our study on risk differences by sex. While we studied the effects of sex-specific hormones, our study analyzed data according to subject reported sex, which could be affected by gender identification. This is most relevant to risk among OC users since these medications would be more likely to be used in those of female gender regardless of sex. Our findings with regard to HRT and reproductive factors would be less likely to be confounded by gender orientation.

In conclusion, we found additional support for the hypothesis that female sex steroids may contribute to the pathogenesis of KC in a population of US women.
1. Hoy WE. Nonmelanoma skin carcinoma in Albuquerque, New Mexico: experience of a major health care provider. Cancer 1996; 77:2489–95.

2. Hayes RC, Leofeltner S, Pilgrim W, et al. Incidence of nonmelanoma skin cancer in New Brunswick, Canada, 1992 to 2001. J Cutan Med Surg 2005; 9:45–52.

3. Rogers HW, Weinstock MA, Harris AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146:283–87.

4. Perera E, Grunsewaran N, Staines C, et al. Incidence and prevalence of non-melanoma skin cancer in Australia: a systematic review. Australas J Dermatol 2015;56:258–67.

5. Karagas MR, Greenberg ER, Spencer SK, et al. Increase in incidence rates of basal and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 1999; 81:555–9.

6. Brewster DH, Bhatti LA, Inglis JH, et al. Recent trends in incidence of nonmelanoma skin cancers in East of Scotland, 1992-2003. Br J Dermatol 2007; 156:295–300.

7. Lomas A, Leonard-Jee B, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166:1069–80.

8. Flohil SC, Seubring J, van Rossum MM, et al. Trends in basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol 2013; 133:913–18.

9. Weinstock MA, Bogaars HA, Ashley M, et al. Nonmelanoma skin cancer mortality: a population-based study. Arch Dermatol 1991; 127:1194–7.

10. Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in The Netherlands: increased incidence rates, but stable relative survival and mortality 1988-2008. Eur J Cancer 2012; 48:2046–43.

11. Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin cancer prevention study group. JAMA 1992; 267:3005–10.

12. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2013; 133:1527–34.

13. Mudigonda T, Pearce DJ, Yentzer BA, et al. The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw 2010; 8:888–896.

14. Xiang F, Lucas R, Hales S, et al. Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978-2012. JAMA Dermatol 2014; 150:1063–71.

15. Gray DT, Suman VJ, Su WP, et al. Trends in the populations-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997; 133:735–60.

16. Birch-Johansen F, Jensen A, et al. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: rapid incidence increase among young Danish women. Int J Cancer 2010; 127:2190–8.

17. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hor-

18. Gray PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of pro-

tate cancer. J Natl Cancer Inst 1996; 88:1127–35.

19. Missmer SA, Elissen AH, Barberii RL, et al. Endogenous estrogen, androgens, and progest-

126:258–67.

20. Asgari MM, Efrid JT, Warton EM, et al. Potential risk factors for cutaneous squamous cell car-

cinoma include oral contraceptives: results of a nested case–control study. Int J Environ Res Pub-

146:272–42.

21. Applebaum KM, Nelson HH, Zena MS, et al. Oral contraceptives: a risk factor for squamous cell carcinoma! J Invest Dermatol 2009; 129:5–10.

22. Birch-Johansen F, Jensen A, Olesen AB, et al. Does hormone replacement therapy and use of oral contraceptives increase the risk of non-

melanoma skin cancer? Cancer Causes Control 2012; 23:379–88.

23. Efrid JT, Teikaud AE, Lea CS, et al. The combined influence of oral contraceptives and human papil-

2014; 127:1194–7.

24. Karagas MR, Waterboer T, Zena MS, et al. Oral contraceptives increase the risk of non-

melanoma skin cancer. J Natl Cancer Inst 1991; 83:835–40.

25. Applebaum KM, Nelson HH, Zena MS, et al. Oral contraceptives increase the risk of non-

melanoma skin cancer. J Natl Cancer Inst 1991; 83:835–40.

26. Gilbert-Diamond D, Zhigang L, Perry AE, et al. Photo-

sensitizing agents and the risk of non-melanoma skin cancer: a population-based case–control study. J Invest Dermatol 2013; 133:913–18.

27. Karagas MR, Waterboer T, Li Z, et al., New Hampshire Skin Cancer Study Group. Genus B human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin population-based case–control study. BMJ 2010; 341:c2986.

28. Robinson SN, Zens MS, Perry AE, et al. Photo-
sensitizing agents and the risk of non-melanoma skin cancer: a population-based case–control study. J Invest Dermatol 2013; 133:913–18.

29. Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in The Neth-

erlands: increased incidence rates, but stable relative survival and mortality 1988-2008. Eur J Cancer 2012; 48:2046–43.

30. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2013; 133:1527–34.

31. Mudigonda T, Pearce DJ, Yentzer BA, et al. The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw 2010; 8:888–896.

32. Xiang F, Lucas R, Shen S, et al. Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978-2012. JAMA Dermatol 2014; 150:1063–71.

33. Gray DT, Suman VJ, Su WP, et al. Trends in the populations-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997; 133:735–60.

34. Birch-Johansen F, Jensen A, et al. Trends in the incidence of nonmelanoma skin cancer in Den-

mark 1978-2007: rapid incidence increase among young Danish women. Int J Cancer 2010; 127:2190–8.

35. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hor-

36. Inoue RM, Su WP, et al. Trends in the incidence of nonmelanoma skin cancer in New Bruns-
wick, Canada, 1992 to 2001. J Cutan Med Surg 2005; 9:45–52.

37. Rogers HW, Weinstock MA, Harris AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146:283–87.